Sponsor worked with Frontage on BE/BA study using IV infusion. The product was approved in tablet form however the sponsor was looking to convert the drug into an injectable liquid as a quick on set for the treatment of severe migraines.
Register to gain access to gated resources.
Thank you for registering!
You now have the option of downloading the resource or viewing the web version below.
This study is aimed at developing a Nanoemulsion formulation of a poorly water-soluble and thermally, oxidatively, and photolytically unstable active pharmaceutical ingredient (API) for ophthalmic application, specifically for the reduction of intraocular pressure (IOP) and to provide neuroprotection.
Frontage develops a full validation of the XTMAB-16 NAb (neutralizing antibody) assay with acceptable drug and target tolerances to guide future clinical trials.
Frontage has developed a next-generation sequencing (NGS)-based method to rapidly determine the genotype of 300+ genes involved in ADME, called the Frontage PGx NGS Test.